Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patients.

Kesimpta (ofatumumab subcutaneous) - Novartis, Genmab

Tysabri (natalizumab) - Biogen, Royalty

http://www.ncbi.nlm.nih.gov/pubmed/42718919

Colyne Betsch; Emmanuel Bernard; Jean-Christophe Ouallet; Jérôme De Seze; Kévin Bigaut; Laurent Kremer; Livia Lanotte; Nicolas Collongues; Yasmine Nivoix

Sep 11, 2026